Mutations in CYP24A1 and idiopathic infantile hypercalcemia

New England Journal of Medicine

Volumn 365, Issue 5, 2011, Pages 410-421

  Schlingmann, Karl P ^a,b   Kaufmann, Martin ^g   Weber, Stefanie ^c   Irwin, Andrew ^g   Goos, Caroline ^b   John, Ulrike ^d   Misselwitz, Joachim ^d   Klaus, Günter ^e   Kuwertz Bröking, Eberhard ^a   Fehrenbach, Henry ^f   Wingen, Anne M ^c   Güran, Tülay ^h   Hoenderop, Joost G ⁱ   Bindels, René J ⁱ   Prosser, David E ^g   Jones, Glenville ^g   Konrad, Martin ^a  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b University Children's Hospital   (Germany)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d JENA UNIVERSITY HOSPITAL   (Germany)

^e Kuratorium für Heimdialyse Pediatric Kidney Center   (Germany)

^f Children's Hospital   (Germany)

^g QUEEN S UNIVERSITY   (Canada)

^h Pediatric Hematology Clinic   (Turkey)

ⁱ RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCITRIOL; CALCIUM; DRUG METABOLIZING ENZYME; FUROSEMIDE; GLUCOCORTICOID; PAMIDRONIC ACID; VITAMIN D;

ANIMAL CELL; ARTICLE; AUTOSOMAL RECESSIVE INHERITANCE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CYP24A1; DEHYDRATION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; ENZYMATIC DEGRADATION; FAILURE TO THRIVE; GENE; GENE FUNCTION; GENE MUTATION; GENETIC RISK; HUMAN; HYPERCALCEMIA; IDIOPATHIC INFANTILE HYPERCALCEMIA; INFANT; KIDNEY CALCIFICATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REHYDRATION; RICKETS; VOMITING;

EID: 79961102329     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1103864     Document Type: Article

References (34)

1. DeLuca HF, Schnoes HK. Metabolism and mechanism of action of vitamin D. Annu Rev Biochem 1976;45:631-66.
2. Institutes of Medicine. Dietary reference intakes for calcium and vitamin D. Washington, DC: National Academy of Sciences, 2011.
3. Fanconi G. Chronic disorders of calcium and phosphate metabolism in children. Schweiz Med Wochenschr 1951;81:908-13. (In German.)
4. Lightwood R. Idiopathic hypercalcaemia with failure to thrive: nephrocalcinosis. Proc R Soc Med 1952;45:401.
5. British Paediatric Association. Hypercalcaemia in infants and vitamin D. BMJ 1956;2:149.
6. Williams JC, Barratt-Boyes BG, Lowe JB. Supravalvular aortic stenosis. Circulation 1961;24:1311-8.
7. Beuren AJ, Apitz J, Harmjanz D. Supravalvular aortic stenosis in association with mental retardation and a certain facial appearance. Circulation 1962;26:1235-40.
8. Lightwood R, Stapleton T. Idiopathic hypercalcaemia in infants. Lancet 1953;265:255-6.
9. Rhaney K, Mitchell RG. Idiopathic hypercalcaemia of infants. Lancet 1956;270:1028-32.
10. Fraser D. The relation between infantile hypercalcemia and vitamin D - public health implications in North America. Pediatrics 1967;40:1050-61.
11. Smith DW, Blizzard RM, Harrison HE. Idiopathic hypercalcemia; a case report with assays of vitamin D in the serum. Pediatrics 1959;24:258-69.
12. Prosser DE, Jones G. Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem Sci 2004;29:664-73. (Pubitemid 39491265)
13. Makin G, Lohnes D, Byford V, Ray R, Jones G. Target cell metabolism of 1,25-dihydroxyvitamin D3 to calcitroic acid: evidence for a pathway in kidney and bone involving 24-oxidation. Biochem J 1989;262:173-80. (Pubitemid 19220946)
14. Reddy GS, Tserng KY. Calcitroic acid, end product of renal metabolism of 1,25-dihydroxyvitamin D3 through C-24 oxidation pathway. Biochemistry 1989;28:1763-9. (Pubitemid 19072051)
15. Quarles LD. Endocrine functions of bone in mineral metabolism regulation. J Clin Invest 2008;118:3820-8.
16. Prosser DE, Guo Y, Jia Z, Jones G. Structural motif-based homology modeling of CYP27A1 and site-directed mutational analyses affecting vitamin D hydroxylation. Biophys J 2006;90:3389-409.
17. Masuda S, Prosser DE, Guo YD, Kaufmann M, Jones G. Generation of a homology model for the human cytochrome P450, CYP24A1, and the testing of putative substrate binding residues by site-directed mutagenesis and enzyme activity studies. Arch Biochem Biophys 2007;460:177-91. (Pubitemid 46589391)
18. Prosser DE, Kaufmann M, O'Leary B, Byford V, Jones G. Single A326G mutation converts human CYP24A1 from 25-OHD3- 24-hydroxylase into -23-hydroxylase, generating 1alpha,25-(OH)2D3-26,23-lactone. Proc Natl Acad Sci U S A 2007;104:12673-8. (Pubitemid 47255213)
19. Hesse V, Siebenhuner M, Plenert W, Markestad T, Aksnes L, Aarskog D. Evaluation of vitamin D "interval administration"for the prevention of rickets in infancy. Kinderarztl Prax 1985;53:383-93. (In German.)
20. Misselwitz J, Hesse V. Hypercalcemia following prophylactic vitamin D administration. Kinderarztl Prax 1986;54:431-8. (In German.)
21. Masuda S, Byford V, Arabian A, et al. Altered pharmacokinetics of 1alpha,25- dihydroxy-vitamin D3 and 25-hydroxyvitamin D3 in the blood and tissues of the 25-hydroxyvitamin D-24-hydroxylase (Cyp24a1) null mouse. Endocrinology 2005;146:825-34. (Pubitemid 40129840)
22. Hamamoto H, Kusudo T, Urushino N, et al. Structure-function analysis of vitamin D 24-hydroxylase (CYP24A1) by site-directed mutagenesis: amino acid residues responsible for species-based difference of CYP24A1 between humans and rats. Mol Pharmacol 2006;70:120-8.
23. Annalora AJ, Bobrovnikov-Marjon E, Serda R, et al. Hybrid homology modeling and mutational analysis of cytochrome P450C24A1 (CYP24A1) of the vitamin D pathway: insights into substrate specificity and membrane bound structurefunction. Arch Biochem Biophys 2007;460:262-73. (Pubitemid 46589389)
24. St-Arnaud R. Targeted inactivation of vitamin D hydroxylases in mice. Bone 1999;25:127-9. (Pubitemid 29322076)
25. St-Arnaud R, Arabian A, Travers R, et al. Deficient mineralization of intramembranous bone in vitamin D-24-hydroxylase-ablated mice is due to elevated 1,25-dihydroxyvitamin D and not to the absence of 24,25-dihydroxyvitamin D. Endocrinology 2000;141:2658-66. (Pubitemid 32269087)
26. Shephard RM, Deluca HF. Plasma concentrations of vitamin D3 and its metabolites in the rat as influenced by vitamin D3 or 25-hydroxyvitamin D3 intakes. Arch Biochem Biophys 1980;202:43-53. (Pubitemid 11128265)
27. Jones G. Pharmacokinetics of vitamin D toxicity. Am J Clin Nutr 2008;88:582S-586S.
28. Deluca HF, Prahl JM, Plum LA. 1,25-Dihydroxyvitamin D is not responsible for toxicity caused by vitamin D or 25-hydroxyvitamin D. Arch Biochem Biophys 2011;505:226-30.
29. Pronicka E, Rowinska E, Kulczycka H, Lukaszkiewicz J, Lorenc R, Janas R. Persistent hypercalciuria and elevated 25- hydroxyvitamin D3 in children with infantile hypercalcaemia. Pediatr Nephrol 1997;11:2-6. (Pubitemid 27049401)
30. Nguyen M, Boutignon H, Mallet E, et al. Infantile hypercalcemia and hypercalciuria: new insights into a vitamin Ddependent mechanism and response to ketoconazole treatment. J Pediatr 2010;157:296-302.
31. Stapleton T, Macdonald WB, Lightwood R. The pathogenesis of idiopathic hypercalcemia in infancy. Am J Clin Nutr 1957;5:533-42.
32. Weisman Y, Harell A, Edelstein S. Infantile hypercalcemia: a defect in the esterification of 1,25-dihydroxyvitamin D? Med Hypotheses 1979;5:379-82. (Pubitemid 9243464)
33. Samuel HS. Infantile hypercalcaemia, nutritional rickets, and infantile scurvy in Great Britain: a British Paediatric Association report. BMJ 1964;1:1659-61.
34. Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011;96:53-8.